Serum 1,25-Dihydroxyvitamin D in Bone Disease

Robert Steendijk, Marc K. Drezner, Mark R. Haussler, Charles R. Scriver, Theresa M. Reade, Hector F. Deluca, Alan J. Hamstra

Research output: Contribution to journalLetter

7 Scopus citations

Abstract

To the Editor: In a recent paper1 Scriver et al. stated that in patients with hypophosphatemic bone disease, active rickets is not observed, while serum phosphate is low and the level of 1α,25-dihydroxyvitamin D is normal. On the other hand, in patients with X-linked hypophosphatemia rachitic bone disease is present with similarly low levels of serum phosphate and decreased concentrations of 1α,25-dihydroxyvitamin D. This finding encouraged the authors to believe that a normal level of 1α,25-dihydroxyvitamin D prevents severe bone demineralization or, perhaps better, severe impairment of mineralization. It is possible to agree with this line of thought if the.

Original languageEnglish (US)
Pages (from-to)434-435
Number of pages2
JournalNew England Journal of Medicine
Volume300
Issue number8
DOIs
StatePublished - Feb 22 1979

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Serum 1,25-Dihydroxyvitamin D in Bone Disease'. Together they form a unique fingerprint.

  • Cite this

    Steendijk, R., Drezner, M. K., Haussler, M. R., Scriver, C. R., Reade, T. M., Deluca, H. F., & Hamstra, A. J. (1979). Serum 1,25-Dihydroxyvitamin D in Bone Disease. New England Journal of Medicine, 300(8), 434-435. https://doi.org/10.1056/NEJM197902223000816